首页> 美国卫生研究院文献>Oncotarget >miR-130b an onco-miRNA in bladder cancer is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression
【2h】

miR-130b an onco-miRNA in bladder cancer is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression

机译:miR-130b是膀胱癌中的一种癌基因miRNA直接受NF-κB调节并通过降低圆柱状菌病的表达来维持NF-κB的活化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Persistent activation of NF-κB signaling is closely related to chronic inflammation and tumorigenesis. Commonly, NF-κB signaling is tightly controlled by multiple feedback loops and regulators, such as the deubiquitinases (DUBs). However, in cancer cells, NF-κB may override these feedbacks through special pathways and lead to the sustained activation. In the present study, we demonstrate that in transitional cell carcinoma (TCC) of bladder, miR-130b plays an oncogenesis role, it enhanced proliferation, invasion and migration of TCC cell, and was highly correlated with tumor progression. On the other hand, NF-κB directly regulated the transcription of miR-130b by binding with its promoter region. Importantly, we verify that, through deceasing the expression of Cylindromatosis (CYLD), a K63-specific DUB and endogenous blocker of NF-κB signaling, miR-130b can in return sustain the persistent activation of NF-κB, which may promote the malignant progression of TCC. Thus, the present study uncovers a potential signaling transduction in which NF-κB is continuously activated, and may provide a novel therapeutic approach for the clinical management of TCC.
机译:NF-κB信号的持续激活与慢性炎症和肿瘤发生密切相关。通常,NF-κB信号传导是由多个反馈回路和调节剂(例如去泛素酶(DUB))严格控制的。但是,在癌细胞中,NF-κB可能会通过特殊途径覆盖这些反馈并导致持续激活。在本研究中,我们证明了miR-130b在膀胱移行细胞癌(TCC)中起着致癌作用,它增强了TCC细胞的增殖,侵袭和迁移,并且与肿瘤进展高度相关。另一方面,NF-κB通过与其启动子区结合直接调节miR-130b的转录。重要的是,我们证实,miR-130b通过降低K63特异性DUB和内源性NF-κB信号传导抑制剂cylindromatosis(CYLD)的表达,反过来可以维持NF-κB的持续活化,这可能促进恶性肿瘤TCC的进展。因此,本研究揭示了一种潜在的信号转导,其中NF-κB被连续激活,并可能为TCC的临床管理提供一种新颖的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号